Alabama is currently home to 1236 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Birmingham, Mobile, Huntsville and Anniston. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Implementation Trial to Evaluate a Population Health Combination Intervention to Meet HIV Testing, Linkage, and Viral Suppression Goals in Alabama
NCT05384145
Recruiting
The purpose of this study is to adapt and evaluate a combination intervention that includes: (1) a data-driven approach to directed community-based HIV testing to areas with high need, (2) Project Connect to expedite linkage to care at time of diagnosis, (3) and a Rapid ART (antiretroviral therapy)Start program, all in Mobile County Health Department (MCHD) jurisdictions in Alabama.
Gender:
ALL
Ages:
13 years and above
Trial Updated:
04/22/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: HIV, HIV Linkage to Care, HIV Testing, HIV Treatment
Register for Updates
Coaching Dementia Caregivers to Master Care-Resistant Behavior
NCT05098652
Recruiting
266 family caregivers will be randomly assigned to either immediate intervention or delayed intervention groups. All caregivers will complete baseline surveys and 3 weeks of daily diaries. The immediate intervention group will receive 12 weeks of CuRB-IT. They will complete 3 rounds of 3-week daily diaries followed by an intermittent survey at 12 week intervals for the next 33 weeks. The delayed intervention group will receive 12 weeks of attention, complete 1 round of 3-week daily diaries follo... Read More
Gender:
ALL
Ages:
Between 18 years and 95 years
Trial Updated:
04/22/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Care-resistant Behavior, Dementia
Register for Updates
Neurophysiological, Behavioral, and Cognitive Networks in Movement Disorders
NCT04061135
Recruiting
The purpose of this study is to investigate the brain activity associated with motor and non-motor symptoms of movement disorders, including Parkinson's disease (PD) and essential tremor. These movement disorders commonly have significant non-motor features, such as depression, cognitive and memory impairment, decreased attention, speech and language disturbances, and slower processing speeds. The investigators are interested in the brain activity associated with these motor and non-motor sympto... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/22/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Movement Disorders
Register for Updates
Sleep for Stroke Management and Recovery Trial
NCT03812653
Recruiting
The purpose of this study is to determine whether treatment of obstructive sleep apnea (OSA) with positive airway pressure starting shortly after acute ischemic stroke (1) reduces recurrent stroke, acute coronary syndrome, and all-cause mortality 6 months after the event, and (2) improves stroke outcomes at 3 months in patients who experienced an ischemic stroke.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/22/2025
Locations: University of Alabama Hospital, Birmingham, Alabama
Conditions: Ischemic Stroke, Sleep Apnea, Sleep Apnea, Obstructive, Stroke, CPAP, Telemedicine, Home Sleep Apnea Test, Randomized Clinical Trial, Multicenter Trial
Register for Updates
Conditioning SCID Infants Diagnosed Early
NCT03619551
Recruiting
The investigators want to study if lower doses of chemotherapy will help babies with SCID to achieve good immunity with less short and long-term risks of complications after transplantation. This trial identifies babies with types of immune deficiencies that are most likely to succeed with this approach and offers them transplant early in life before they get severe infections or later if their infections are under control. It includes only patients receiving unrelated or mismatched related dono... Read More
Gender:
ALL
Ages:
Between 0 years and 2 years
Trial Updated:
04/22/2025
Locations: Univeristy of Alabama at Birmingham, Birmingham, Alabama
Conditions: SCID
Register for Updates
Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)
NCT06098079
Recruiting
A randomized, double-blinded, placebo controlled study intended to capture cardiovascular outcomes during real-world use of naltrexone/bupropion (NB).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/21/2025
Locations: Accel Research Sites Network, Birmingham, Alabama
Conditions: Obesity
Register for Updates
A Study to Evaluate Long-term Safety of Ecopipam Tablets in Children, Adolescents and Adults With Tourette's Disorder
NCT06021522
Recruiting
The primary objective of this study is to evaluate the long-term safety and tolerability of ecopipam tablets in children (greater than or equal to \[\>=\] 6 and less than \[\<\] 12 years of age), adolescents (\>=12 and \<18 years of age), and adults (\>=18 years of age) with Tourette's Syndrome (TS).
Gender:
ALL
Ages:
6 years and above
Trial Updated:
04/21/2025
Locations: Harmonex, Inc., Dothan, Alabama
Conditions: Tourette Syndrome
Register for Updates
Embolization of the Splenic Artery After Trauma
NCT05128955
Recruiting
Our aim is to conduct a multi-center, Bayesian, randomized clinical trial to evaluate the primary technical success of coils and vascular plugs for proximal splenic artery embolization in the setting of high-grade splenic trauma. The investigator has previously demonstrated the feasibility of such a study in a single center pilot trial.
Gender:
ALL
Ages:
15 years and above
Trial Updated:
04/21/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: High-grade Splenic Injuries
Register for Updates
PRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis
NCT04971720
Recruiting
Obese individuals have a higher prevalence of nocturnal hypertension and non-dipping blood pressure (BP). These conditions are associated with an increased risk of cardiovascular (CV) events and death. Natriuretic Peptides (NPs) are hormones produced by the heart which directly regulate BP by causing dilation of blood vessels and by removing sodium and water from the body. NPs have a 24-hour day-night rhythm and this controls the day-night rhythm of BP as well. The NP-BP rhythm relationship is b... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/21/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Obesity, Cardiovascular Diseases, Hypertension, Nocturnal Blood Pressure, Natriuretic Peptides, Renin-Angiotensin-Aldosterone System
Register for Updates
Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy
NCT05180773
Recruiting
The study will enroll 200 women newly diagnosed with peripartum cardiomyopathy within 5 months postpartum in a randomized placebo controlled trial of bromocriptine therapy to evaluate its impact on myocardial recovery and clinical outcomes. Given that bromocriptine prevents breastfeeding, an additional 50 women with peripartum cardiomyopathy excluded from the trial due to a desire to continue breastfeeding but meeting all other entry criteria will be followed in an observational cohort.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/19/2025
Locations: University of Alabama Birmingham, Birmingham, Alabama
Conditions: Peripartum Cardiomyopathy, Postpartum
Register for Updates
Trial to Evaluate Safety and Efficacy of KPI-012 Ophthalmic Solution in Participants With PCED
NCT05727878
Recruiting
The primary objective of the study is to investigate the safety and efficacy of KPI-012 compared to vehicle in participants who have a documented clinical diagnosis of PCED.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/18/2025
Locations: Principal Investigator, Dothan, Alabama
Conditions: Persistent Corneal Epithelial Defect
Register for Updates
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
NCT05633654
Recruiting
The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which includes either pembrolizumab or pembrolizumab plus capecitabine in participants with triple negative breast cancer that still remains after surgery and pre-surgical treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/18/2025
Locations: Alabama Oncology, Birmingham, Alabama
Conditions: Triple Negative Breast Cancer
Register for Updates